Life Sciences Archive » January, 2014

Life Sciences - January, 2014

320 articles

• Edison Inks Potential $4.3B R&D Deal With Japan Pharma Co.
• FDA Probes Testosterone Products For Fatal Risks
• FTC Clears Thermo Fisher's $14B Life Tech Buy With GE Deal
• Precision BioSciences, Cellectis Settle Longtime Patent Feud
• Device Co. Pleads Guilty To Hiding Toxicity Data From FDA
• Rotech Judge Slashes Baker & McKenzie Fee Request
• Sandoz Asks High Court To Toss Fed. Circ. Allergan Ruling
• Abbott Can't Escape FCA Suit Over Drug Marketing, Kickbacks
• FTC New Year's Resolution: End Deceptive Weight-Loss Ads
• Novartis Sues Noven Over Generic Dementia Patch
• Endo Must Shed Drugs For $225M Boca Buy, FTC Says
• Female Powerbrokers Q&A: McAndrews' Sharon Hwang
• Female Powerbrokers Q&A: Faegre Baker's Kathy Noecker
• 'Reasonable Certainty' Remains Uncertain
• Class Cert. Denied In Pfizer Pay-For-Delay Suit
• Judge Nixes Remand Bid In J&J Infant's Tylenol Suit
• Waxman's Retirement Creates DC Policymaking Void
• Boehringer Docs In Pradaxa MDL Unsealed By Judge
• FDA Tells Consumers To Avoid 4 Weight-Loss Supplements
• Zimmer Accuses Stryker Of Plot To Poach Employees
• Plaintiffs Bar Targets Dietary Supplement Efficacy Claims
• Suit Over Costa Rican Probe Of Atty Can Stay In Fla.
• Drugmakers Defend No-Cash Patent Deals Post-Actavis
• Generics Lobby Floats Alternative To FDA Drug Labeling Plan
• Female Powerbrokers Q&A: Norton Rose's Yvonne Puig
• Female Powerbrokers Q&A: Orrick's Laurie Strauch Weiss
• Waxman, Longtime Leader In The House, To Retire
• Workplace Culture: The Real Pathway To Change
• Surgiview Says It's Not Liable For $37M Ex-Parent Owed
• Possible Sanctions For Takeda In Actos Bladder Cancer MDL
• Patheon Can't Shake Procaps Suit Over $255M Merger
• Star Scientific Action Halted As Feds Pursue Ex-Va. Gov.
• Martoma Witness Calls SAC's Cohen 'Greatest Trader' Ever
• Top DOJ Atty Outlines Pharma Fraud Enforcement
• Wilson Sonsini Reps Fluidigm In $207M DVS Sciences Deal
• Cipro Buyers, Generics Cos. Duel Over Actavis Ruling
• Eli Lilly Sues Par Pharma To Block Generic Effient
• Merz, Shionogi Shielded From Classen IP Suit, Judge Rules
• What Attorneys Should Know About FDA's MedWatch Data
• Google Wants Shareholder Suit Over $500M Ad Deal Nixed
• FDA Leaves Beverage-Labeling Questions Unanswered
• And Now A Word From The Panel: The Year In Review
• Female Powerbrokers Q&A: Goodwin Procter's Joanne Gray
• Female Powerbrokers Q&A: Taft's Barbara Duncombe
• Obama Asserts Executive Power In State Of The Union Speech
• 4th Circ. Tosses Generic-Drug Injury Appeal Against Pliva
• Arbitration Order Staying Suit Not Appealable, 9th Circ. Says
• Allergan Dodges Class Action Over Pricey Eye Drops
• $2.6M Olympus Shareholder Deal Gets Green Light
• J&J Beats $258M Risperdal Verdict In Split La. High Court
• Bankrupt MedLab To Sell Units To LabCorp For $10.5M
• Prosecution Rests In Martoma Insider Trading Case
• Merck, Bristol-Myers Settle With Generics Co. Over HIV Drug
• FTC Says Cephalon Put Ex-GC's Advice In Play
• Hydroxycut False Ad Claims Must Be Clarified, Judge Says
• FDA Wants To Review Drug Companies' Posts And Tweets
• Sarepta Accused Of Misleading Investors On MD Drug
• FDA Scolds Texas Drugmaker Over STD Product Promos
• GNC Hit With Suit Claiming Diet Pills Led To Liver Damage
• Mylan Generic Infringes Endo's Frova Patent, Judge Says
• Atty Fights Former Firm's Attempt To Arbitrate Fees Row
• Calif. Court Reverses Preemption Of Medtronic Injury Suit
• Female Powerbrokers Q&A: Young Conaway's Pauline Morgan
• Female Powerbrokers Q&A: Phelps Dunbar's Nan Alessandra
• J&J Beats $600M Stent Patent Verdict For Good
• Wash. Joins Suit Over Novartis Exjade Kickbacks
• Fla. Supreme Court OKs Medical Marijuana Ballot Initiative
• Eckert Seamans Adds Ex-Bayer General Counsel To PL Group
• Deals Rumor Mill: Carlyle, Vodafone, Altegrity
• DePuy Just Can't Shake Those Hip Replacement Lawsuits
• Loeb Adds Ex-Porzio Partner For New FDA Regulatory Practice
• J&J Urges FDA Deference In Baby Wash False Ad Action
• 3rd Circ. To Review Venue Ruling In GSK Birth Defects Case
• Female Powerbrokers Q&A: Crowell's Angela Styles
• Female Powerbrokers Q&A: WilmerHale's Susan Murley
• Actavis Only Requires Scrutiny Of Cash Deals, Judge Says
• 7th Circ. Reverses Boehringer Depo Order In Pradaxa MDL
• Cochlear Hit With $131M Verdict In Implant Patent Trial
• Steptoe & Johnson Opens Office In Palo Alto
• 5 Takeaways From FDA Overture On Generic-Drug Approvals
• Fed. Circ. Junks Patents On Treatment-Picking Program
• Covidien Wins Surgical Tool Patent Suit By J&J Unit
• Shuttered Debt Collector Withheld $90M, Quest Says
• What's In The Wash? FDA Rules On Antibacterial Soaps
• Clinics Ink $2M FCA Deal In Reimported Drugs Case
• 6th Circ. Won't Rehear Generic-Reglan Injury Claims
• Thoratec Hit With Shareholder Suit Over Device Recall, Study
• Teva, Boehringer Slapped With New Pay-For-Delay Suit
• St. Jude Can't Shake Defective Defibrillator Suits
• Female Powerbrokers Q&A: Hughes Hubbard's Beinecke
• Female Powerbrokers Q&A: Willkie's Margery Neale
• McKesson Salvages Celesio Buy With Reworked Deals
• Cephalon Says Patent Toss Doesn't Bar Pay-For-Delay Defense
• Cohen Real Target In Probe Of SAC's Martoma, Witness Says
• Another Ranbaxy Drug Plant Fails FDA Test
• GOP Lawmakers Rip FDA's Generic-Drug Labeling Overhaul
• Pa. Pharma Ruling Opens New Front In Mass Tort Battles
• Baxter Sues J&J For Violating Floseal Patents
• Medicare Billing Records Give FCA Whistleblowers New Ammo
• USPTO Says Group Lacks Standing In Stem Cell Patent Appeal
• Norton Rose Fulbright Draws In 2 Shook Hardy Health Pros
• Shire Doesn't Have To Return Docs In Generic Dispute
• FDA Analyzing Foods For Caramel Coloring Danger
• Philips Didn't Interfere With Worker's New Job, Judge Rules
• Eli Lilly Sues Glenmark Over Cancer Drug ANDA
• Mylan Sues Insys Over Attempt To Cut Off Distribution Deal
• Sen. Calls For Probe Into Herbalife Pyramid Scheme Claims
• Female Powerbrokers Q&A: Fluet Huber's Jennifer Huber
• Female Powerbrokers Q&A: Goldberg Segalla's Berdzik
• Alibaba, PE Partner Sink $171M Into Drug Data Venture
• Proposed FDA Rule Could Bring Failure-To-Warn Liability
• Ex-Prof. Says Martoma Ditched Him After Tips Led To Trades
• Justices' Burden-Of-Proof Ruling Gives Licensees A Leg Up
• EBay, PayPal Hit With Suit Over Prosthetics Listings
• FDA Updates Mad Cow Disease Guidance For Medical Devices
• Pfizer Escapes Whistleblower Suit Over Lipitor Marketing
• Cigna Coverage Row Shouldn't Be Arbitrated, 3rd Circ. Told
• Fed. Circ. Strikes Down Medtronic Heart Valve Patent
• FDA Overhauls 'Dear Doctor' Guidance On Drug Risks
• Nu Skin Hit With Investor Suit Over China Operations
• 23andMe Faces Suit Over Recently Banned DNA Tests
• Affymax Largely Ducks Investor Suit Over Anemia Drug
• Female Powerbrokers Q&A: Anderson Kill's Pamela Hans
• Pharma Can Be Liable For Design Negligence: Pa. High Court
• Female Powerbrokers Q&A: Cozen O'Connor's Mayes
• High Court Rules Patent Owners Have Burden Of Proof
• Quest Diagnostics Puts Up $570M For PE-Backed Lab Co.
• Reversal Over Sacked Gay Juror To Guide Jury Selection
• AstraZeneca Seeks Full Rehearing Of Generic Drugmaker Win
• Prof Says Ex-SAC Manager Got Details On Drug Study
• FDA Balks At Trial Design For Amarin's Fish Oil Drug
• Conflicts Doom Baker & McKenzie Fee Bid, Rotech Says
• Making Sense Of CLS Bank In View Of Prometheus, Alappat
• Gay Juror Wrongly Booted In GSK-Abbott Row, 9th Circ. Says
• Pa. Appeals Court Upholds Transfer Of Asbestos Cases
• Teva Asks Supreme Court To Weigh De Novo Review
• FDA Warns Medical Food Co. Amid Continuing Crackdown
• Spectranetics CEO Can't Shake False Statement Conviction
• Ted Kennedy Jr. Joins Epstein Becker Green's Health Group
• NAD Refers Salonpas Ad Claims To FDA, FTC
• Judge Not Racially Biased Against Investor, 2nd Circ. Says
• 6th Circ. Revives Mylan Wrongful Death Suit
• China Says IP Crackdown Led To 60K Arrests In 2013
• Female Powerbrokers Q&A: Alston & Bird's Nicki Carlsen
• Female Powerbrokers Q&A: Shackelford's Nicole LeBoeuf
• Elliott Ups Celesio Stake After Failed $8.5B McKesson Buy
• NuPathe Nixes Endo Deal, OKs $114M Teva Takeover
• Merck Gender Bias Suit Swells To $250M After Plaintiffs Added
• Jury Clears Abbott In Tainted Formula Injury Suit
• Professor Testifies He Tipped Ex-SAC Manager Martoma
• Device Cos. Get FDA Guidance On Computer Simulation
• Warner Chilcott Contraceptive Patent Upheld By Judge
• Drug Cos. Say Noerr Doctrine Bars FTC's Pay-For-Delay Suit
• Avanir Faces Investor Suit Over 'Tax Deductible' Claims
• Altaris Strikes $130M Deal To Buy Endo's HealthTronics
• Shire Sells Dermagraft To Organogenesis At $650M Loss
• Female Powerbrokers Q&A: Jackson Kelly's Ellen Cappellanti
• Female Powerbrokers Q&A: Cole Schotz's Randi Kochman
• 3 Cost-Cutting Resolutions Law Firms Can't Afford To Break
• After Dolly: The Status Of Nonhuman Clones In Patent Law
• Senate Sends $1T Federal Spending Bill To Obama's Desk
• Alvogen Set To Gain Majority Of Lotus In $200M Asset Swap
• Aegerion Hit With Shareholder Suit Over Juxtapid Labeling
• Gentium Investors Sue Over $1B Jazz Pharma Deal
• Iovate Stuck In Bodybuilding Supplement False Ad Suit
• Savient Hid Cash Woes Before Ch. 11 Sale, Investors Say
• Female Powerbrokers Q&A: Fox Rothschild's Resnick
• Female Powerbrokers Q&A: Roetzel's Erika Haupt
• Carlyle Puts Up $4B For J&J's Blood-Testing Unit
• China Conditionally OKs Thermo Fisher's $14B Life Tech Buy
• Clinical Labs Under ACA: Challenge And Opportunity
• 4 Lessons From FDA's Social Media Guidance
• Affymax Says It Didn't Mislead Investors About Anemia Drug
• Fed. Circ. Ruling Clears Way For Longer Patent Terms
• NuVasive Can't Dodge Orthopedic Patent Suit
• Ex-SAC Manager Had Early Read On Study, Court Hears
• Life Sciences Group Of The Year: WilmerHale
• Vitamin Shoppe Ducks Bodybuilding Supplement False Ad Suit
• House Passes $1T Federal Spending Bill
• Deals Rumor Mill: Time Warner, Carlyle, Aeropostale
• Jury Awards Edwards $393M In Medtronic Valve Patent Row
• Female Powerbrokers Q&A: Holland & Hart's Liz Sharrer
• Female Powerbrokers Q&A: Anderson Kill's Rhonda Orin
• McCarter & English Picks Up Porzio Product Liability Vet
• Facts Show Patent Trolls Not Behind Rise In Suits
• A Push By The USPTO For Faster Patent Processing
• Doctor Says He Tipped Former SAC Manager Martoma
• Allergan Stymies Generic Glaucoma Med In Patent Trial
• Merck Recalls Supply Of Cholesterol Drug Liptruzet
• Life Sciences Group Of The Year: White & Case
• Siemens Beats Whistleblower's FCA Suit Over VA Charges
• Teva Didn't Infringe OxyContin Patents, NY Judge Rules
• FDA Outlines New Stance On Patient-Specific Devices
• Deals Rumor Mill: Forbes, Pfizer, Bankia
• $1T Bill Ups Tech, Finance Budgets, Cuts ACA Funds
• Big Pharma's Pricing Power Imperiled By Part D Overhaul
• Roche Loses Last Shot At Booting NJ Accutane Judge
• AstraZeneca Can't Duck Pharmacies' Claims In Nexium MDL
• Female Powerbrokers Q&A: Debevoise's Mary Beth Hogan
• Female Powerbrokers Q&A: Sanford's Katherine Kimpel
• McKesson's $8.5B Bid for Celesio Falls Flat
• Ropes & Gray Reps Genzyme In $700M Deal For Alnylam Stake
• Pfizer Faces Whistleblower Suit Over Lipitor Marketing
• FDA Should Assume Authority Over Human Cloning
• Forest Can't Nix Mo. Class In Antidepressant Marketing MDL
• FDA Gives Drugmakers Taste Of Social Media Rules
• Life Sciences Group Of The Year: Paul Hastings
• NJ Court Orders Report On Medical Marijuana Program
• Jones Day Adds Food And Drug Partner From Akin Gump
• Female Powerbrokers Q&A: Otterbourg's Melanie Cyganowski
• Female Powerbrokers Q&A: Epstein Becker's Joan Disler
• FTC Dissent Could Spell End To Strict Health Ad Standard
• Ex-SAC Manager Martoma Sought 'Illegal Edge,' Jurors Hear
• (Foreign) Food For Thought: Risks From Chinese Imports
• Science Question Hangs Over High Court Birth Control Case
• Justices Take 2 Patent Cases On Inducement, Indefiniteness
• Life Sciences Group Of The Year: Kirkland & Ellis
• Mintz Levin Nabs Health Care FCA Pro From Patton Boggs
• FDA Pushes Hospitals To Buy From Registered Compounders
• Alcon Aims To Halt Micro Labs' Generic Glaucoma Drug
• Female Powerbrokers Q&A: Wilson Elser's Publicover
• Female Powerbrokers Q&A: Fowler White's Rhea Law
• Boston Scientific Loses Bid To Lift Ban On Catheter Sales
• Inequitable Conduct Won't Undo Attorney-Client Privilege
• 4th Circ. Leaves 'Excessive' FCA Fines Up In The Air
• Settlement Tax Breaks Will Continue Despite JPMorgan Deal
• NJ Senate OKs Bill To Redesignate Medical Marijuana
• NJ High Court Stays Accutane Case, Weighs Judge's Recusal
• Ex-SAC Manager Martoma Was Tossed From Harvard Law
• Fed. Circ. Mulls Rule For Declaratory Judgment Jurisdiction
• Zacadia Overreached In Herbalife $400M Estate, Court Says
• Life Sciences Group Of The Year: Covington & Burling
• DC Circ. Revives K-V's FDA Enforcement Row
• 8th Circ. Affirms Novartis Loss In Aredia, Zometa Suit
• Bard Vaginal Mesh Bellwether Put On Hold
• Female Powerbrokers Q&A: Duane Morris' Sharon Caffrey
• Female Powerbrokers Q&A: Novak Druce's Katy Basile
• Deals Rumor Mill: Novartis, Statoil, Lanco
• McKesson Woos Hedge Fund With Heftier $8.4B Celesio Bid
• GSK Blasts Appeal Bid In Pa. Paxil Venue Dispute
• Forest Lab's Lexapro Causes Fatal Birth Defects, Mom Says
• Teva Says FTC Can't Draw It Into Pay-For-Delay Case
• Steve Cohen Testimony Barred From Martoma Trial
• BioScrip Agrees To Pay $15M In FCA Kickback Suit
• Senators Seek More Clarity On Fed. Agency Settlements
• Laxatives Can Lead To Kidney Injury, Death, FDA Warns
• NuPathe Gets $114M Takeover Bid After Inking Deal With Endo
• Medical Device Co. Found To Infringe Infusion Pump Patent
• FDA Approves Bristol-Myers, AstraZeneca Diabetes Drug
• Pfizer Investors Ask 3rd Circ. To Revive Alzheimer's Drug Row
• Forest Labs Spends $3B For Specialty Pharma Co. Aptalis
• Deals Rumor Mill: McKesson, New York Times, Shell
• Recent Evolutions In The Doctrine Of Patent Exhaustion
• Female Powerbrokers Q&A: Arnstein's Kathleen Gilligan
• Female Powerbrokers Q&A: Faegre Baker's Maureen Maly
• ArthroCare To Pay $30M To End $400M Securities Fraud Probe
• NJ Senate OKs Bill To Require Coverage Of Pain Meds
• FDA Splits Approach To Diabetes Meter Approvals
• NY High Court Mulls Test For Recall-Related Damages
• FTC Halts Supplement Marketers' False Ads, Lax Data Control
• EU Clears Celgene's Abraxane To Treat Pancreatic Cancer
• Duty To Warn Doctrine Weakened For Drugmakers
• Zoll Medical Hits Philips With New Suit In Defibrillator IP War
• J&J Loses Bid To Nix Levaquin Award In 8th Circ.
• Surge Of FDA Activity Caps Quiet Year Of Promo Discipline
• Judge Clears Ex-Ameritox Employee's Jump To Millennium
• Bradley Arant Adds Big Pharma Defense Expert In Miss.
• Female Powerbrokers Q&A: Quarles & Brady's Sarah Coyne
• Female Powerbrokers Q&A: Fox Rothschild's Brett Axelrod
• Bogus Weight Loss Claims Cost Cos. $34M In FTC Settlements
• Novartis Sued Over 'Virus Production' Patent For Flu Shots
• Bankrupt Landauer Gets Nod for $22M Sale To Quadrant
• FDA Floats Plan To Streamline New Drug Trials
• 6 Lessons For Lawyers From Feds' 2013 FCA Haul
• Millennium Labs Says VeriMed Stole Drug Report Name
• Bard Can't Get Memos Excluded From Vaginal Mesh Trial
• Medtronic Pays $160M Cash For Implantable Device Maker
• Boehringer, Teva Sued Again Over Deal To Delay Generic
• 'Datalink' Includes Wireless Tech, Hill-Rom Tells Fed. Circ.
• FTC Hits Maker Of Diet Supplement Products Over Ad Claims
• Deals Rumor Mill: Time Warner, Liberty, KKR
• Enzo Award Raised To $61M In DNA Patent Fight
• Female Powerbrokers Q&A: Ideal Legal Group's Evie Jeang
• Female Powerbrokers Q&A: Akin Gump's Christine LaFollette
• Thermo Fisher Sends $1B In Assets To GE In Deal With EU
• 2013 Provided Few Small-Molecule Decisions
• 7th Circ. Blocks Boehringer Workers' Depos In Pradaxa MDL
• Covington Nabs Ex-Mayer Brown Life Sciences Pro
• Boehringer, Teva Sued Over $120M Pay-For-Delay Deal
• Pa. Appeals Court Favors J&J Unit In Nonsolicitation Spat
• Travelers Told To Hand Heparin Docs To American Capital
• How FDA Would Alter Use Of Antibiotics In Food Animals
• Female Powerbrokers Q&A: Choate's Brenda Jarrell
• Female Powerbrokers Q&A: Bond Schoeneck's Ginny Robbins
• TPG-Backed IMS Seeking $100M In Return To Public Markets
• Novartis Can't Dodge $2.2M Jaw Injury Verdict
• Abbott Settles Stent Kickbacks Case For $5M
• Novartis Jacked Up Painkiller Prices, Class Action Claims
• 3rd Circ. False Ad Ruling No Class Action Killer, Bayer Says
• Dendreon Execs Can't Escape Class Suit Over Stock Sales
• 2 Traps For Unwary ANDA Filers
• Thompson Stem Cell Patent Appeal Should Be Dismissed
• When File Type Matters In E-Discovery
• Roche Ducks FCA Suit Over Nonexistent Lab Tests
• Advanced Cell Agrees To Pay $4M Over Alleged Stock Scheme
• Ameritox Lied About Evidence Destruction, Millennium Says
• Fed. Circ. Finds No Preemption In Eyelash Competition Suit
• Concussion-Injury Supplement Claims Draw FDA's Ire
• PE-Backed Biotech Co. UniQure Eyes $75M IPO
• Pa. Court Voids $28M Verdict Against Zimmer, Marketing Co.
• Defendant In Alleged Drunk Insider Trading Case Settles
• Female Powerbrokers Q&A: Ulmer & Berne's Patty Shlonsky
• Female Powerbrokers Q&A: Fish's Cynthia Walden
• The Year Ahead In Pro Bono
• The Next Supreme Court Cases To Shape Patent Law
• 10 New Year's Resolutions To Boost Firm Gender Diversity
• Law360 Names Law Firms Of The Year
• Law360 Names Practice Groups Of The Year
• Life Sciences Cases To Watch In 2014
• Life Sciences Regulation And Legislation To Watch In 2014